Efficacy and tolerability of zoledronic acid vs risedronic acid for the prevention and treatment of osteoporosis in men receiving glucocorticoids

Trial Profile

Efficacy and tolerability of zoledronic acid vs risedronic acid for the prevention and treatment of osteoporosis in men receiving glucocorticoids

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2012

At a glance

  • Drugs Risedronic acid; Zoledronic acid
  • Indications Male osteoporosis
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 01 Jan 2012 Results published in Bone.
    • 18 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top